Mitchell Kapoor
H.C. Wainwright & Co, LLC, Research Division

Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at H.C. Wainwright and the covering analyst for Lyell. Today, I have the pleasure of welcoming Lynn Seely, the CEO of the company.

Today, we're going to have a fireside chat, talk a lot about the CD19/20 space, what they have going on in colorectal cancer and anything else that Lynn thinks would be important to discuss.

Mitchell Kapoor
H.C. Wainwright & Co, LLC, Research Division

So maybe with that, you could just start by giving those who are not up to speed with the story, a brief overview of the company and the current initiatives and maybe just an overview of the data that we've seen so far.

Lynn Seely
Principal Executive Officer, President, CEO & Director

Great. Well, thank you for having me here today. I will be making forward-looking statements for the record, so consult our website and securities filings.

For those who aren't as familiar with Lyell, we are a cell therapy company developing next-generation cell therapies, both for hematologic malignancies as well as for solid tumors. And we have 2 lead programs in the clinic, both targeting large markets. The first is our -- is ronde-cel, our CD19/CD20 dual-targeted CAR, which we're developing really to become the standard of care in the $3 billion CAR T cell CD19 marketplace that's established today in large B-cell lymphoma. And then secondarily, we have a program for metastatic colorectal cancer, which is a very novel CAR, which, we think, is a really, obviously, large market surging in young people. And